SK Biopharmaceuticals Pays $350M Upfront to Accelerate Biohaven’s Epilepsy Drug Toward 2029 Launch

By Dr. Zubair Khalid, DVM, MS, PhD ·

SK Biopharmaceuticals Pays $350M Upfront to Accelerate Biohaven’s Epilepsy Drug Toward 2029 Launch

Key Takeaways

  • SK Biopharmaceuticals has acquired rights to Biohaven Pharmaceuticals' Kv7 ion channel activator for epilepsy, with an upfront payment of $350 million and a total potential deal value of $795 million.
  • The therapeutic mechanism targets Kv7 ion channels, which are critical for regulating neuronal excitability by modulating potassium flux.
  • This Kv7 channel activation represents a distinct pharmacological approach compared to many existing antiseizure medications that primarily modulate sodium or calcium channels.
  • The strategic acquisition aims to bolster SK Biopharmaceuticals' existing epilepsy franchise and potentially address unmet needs in refractory epilepsy populations.
  • The projected 2029 launch timeline suggests the drug is in early-to-mid-stage clinical development, requiring significant investment in further trials and regulatory submissions.
  • The substantial upfront payment underscores investor confidence in novel neurological targets and the therapeutic potential of ion channel modulation in treating complex neurological disorders.

SK Biopharmaceuticals has entered a deal worth up to $795 million with Biohaven Pharmaceuticals to advance an epilepsy therapy. The agreement includes a $350 million upfront payment from SK Biopharmaceuticals. The drug is a Kv7 ion channel activator intended for epilepsy. The companies aim to bring the therapy to market by 2029.

The deal strengthens SK Biopharmaceuticals’ epilepsy portfolio. Biohaven will receive milestone payments beyond the upfront sum, bringing the total potential value to $795 million.

Kv7 ion channels help regulate neuronal firing. Activators of these channels represent a different mechanism from many existing antiseizure drugs, which typically target sodium or calcium channels. This approach may offer new options for patients with epilepsy who do not respond to current treatments. For the biotech industry, the large upfront payment signals confidence in early-stage neurology assets and reflects the continued interest in ion channel modulation as a therapeutic strategy.

Source: original report